Sutro Biopharma (STRO) Total Current Liabilities (2017 - 2026)

Sutro Biopharma has reported Total Current Liabilities for 9 years, with the latest figure at $75.1 million in Q4 2025.

• Quarterly Total Current Liabilities fell 43.03% year-over-year to $75.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $75.1 million (down 43.03% YoY) and the FY2025 annual result came in at $75.1 million, down 43.03% from the prior year.
• Total Current Liabilities improved to $75.1 million in Q4 2025 per STRO's latest filing, from $71.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $133.0 million in Q1 2025 and troughed at $22.7 million in Q1 2021.
• A 5-year average of $72.8 million and a median of $69.5 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 93.65% in 2024, then tumbled 45.24% in 2025.
• Over 5 years, Total Current Liabilities stood at $41.7 million in 2021, then jumped by 59.45% to $66.5 million in 2022, then surged by 40.87% to $93.7 million in 2023, then soared by 40.69% to $131.9 million in 2024, then slumped by 43.03% to $75.1 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $75.1 million, $71.9 million, and $74.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.